Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , 21. Mai 2013 ... die die Firmen OMNIlife science® Inc., Enztec Ltd. ... hat zwei neue, erfahrene Mitglieder in die ... , eine erfahrene Führungspersönlichkeit aus der Orthopädie, ... David Johnson , anerkannter Experte ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... 2013 RenovoRx ( www.renovorx.com ) has been ... Award at TiEcon 2013, the world,s largest annual convention ... quality of entrepreneurial ideas. RenovoRx was honored on Saturday, ... Clara Convention Center. The ... most enterprising startup companies across five verticals: Internet, Software, ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2
... , SAN DIEGO, Dec. 9 ... that the Company,s Principal Executive Officer, Brian M. Culley, will ... Life Sciences On-line Forum on December 15, 2009 at 9:30 ... audio webcast with slide presentation at www.informedinvestors.com , a ...
... Supermarket retailer Giant Eagle® Inc., is receiving an award from ... 12th Annual Cheers Awards reception held in Las Vegas. The ... a superlative standard of excellence for others to follow in ... , The Giant Eagle Pharmacy is being ...
Cached Medicine Technology:Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... MedMar Healing Center announces their participation in the CannaCommunity ... businesses, including MedMar Healing Center, doctors, and clubs, are coming ... to raise food to help area kids who have been ... years. , “We like being able to give back ... Chloupek of MedMar Healing Center. “Taking part in the food ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) Research into genetic ... the University of Colorado School of Medicine may lead ... to a paper published online by JAMA . ... helps predict survival in some cases of pulmonary fibrosis, ... three years. As a result of the study, researchers ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... making inroads, CDC says , , TUESDAY, June 24 ... 2007, an increase of more than 3 million over two ... Tuesday. , In addition, another 57 million Americans had pre-diabetes, ... was some good news. Over two years, the proportion of ...
... engineering Assistant Professor Adela Ben-Yakar at The University of ... destroys a single cell while leaving nearby cells intact, ... epilepsy and other diseases. , "You can remove a ... cells above and below it," Ben-Yakar says. "And you ...
... Traumatic Brain Injury population, both military and civilian, is on the ... rise,Proposed ... ... Mich., June 24 The number of Michigan,residents living with traumatic brain injury (TBI) is ...
... escalate, so should awareness of how to play safely ... warmer weather,extended daylight hours, and a host of outdoor ... to take advantage of more,time under the sun. With ... Memorial Hospital warn against overexposure to the,sun, which can ...
... are,highlights from the June issue of Mayo Clinic ... as you wish. Reprinting is allowed for a ... the following,subscription information as your editorial policies permit: ... 800-333-9037, extension 9PR1., New Scanning Technology Offers ...
... ... Uninsured Population, ATLANTA, June 24 Today, Blue Cross ... called SmartSense,and Premier that will provide Georgians with more affordable options ... are price conscious,and want solid protection to cover the essentials. "Georgians ...
Cached Medicine News:Health News:24 Million Americans Had Diabetes in 2007 2Health News:Laser surgery probe targets individual cancer cells 2Health News:Brain Injury Association of Michigan Outlines the Current State of Brain Injury 2Health News:Brain Injury Association of Michigan Outlines the Current State of Brain Injury 3Health News:Brain Injury Association of Michigan Outlines the Current State of Brain Injury 4Health News:Brain Injury Association of Michigan Outlines the Current State of Brain Injury 5Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 2Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 3Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 4Health News:June 2008 Mayo Clinic Health Letter Highlights New MRI Scanning Technology, Obesity-Related Cancer, and Do-It-Yourself Massage 2Health News:June 2008 Mayo Clinic Health Letter Highlights New MRI Scanning Technology, Obesity-Related Cancer, and Do-It-Yourself Massage 3Health News:June 2008 Mayo Clinic Health Letter Highlights New MRI Scanning Technology, Obesity-Related Cancer, and Do-It-Yourself Massage 4Health News:Blue Cross and Blue Shield of Georgia Introduces New Individual Products 2Health News:Blue Cross and Blue Shield of Georgia Introduces New Individual Products 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: